Apakah dividen Eisai Co aman?
Eisai Co meningkatkan dividen sejak 1 tahun.
Dalam kurun waktu 10 tahun terakhir, Eisai Co telah meningkatkan sebesar 0,647 % setiap tahunnya.
Dalam kurun waktu 5 tahun, naik pembagian dividen meningkat sebesar 0 %.
Analis memperkirakan untuk tahun fiskal yang sedang berjalan akan terjadi pertumbuhan sebesar Kenaikan Dividen%.
Eisai Co Aktienanalyse
Apa yang dilakukan Eisai Co?
Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company.
Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries.
Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world.
The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases.
Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA.
Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery.
Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields.
Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable.
Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co adalah salah satu perusahaan paling populer di Eulerpool.com.Rencana tabungan saham menawarkan kesempatan menarik bagi investor untuk membangun kekayaan jangka panjang. Salah satu keuntungan utamanya adalah efek rata-rata biaya: Dengan berinvestasi dalam jumlah tetap secara reguler ke dalam saham atau dana saham, otomatis anda akan membeli lebih banyak saham ketika harga rendah, dan lebih sedikit ketika harga tinggi. Hal ini dapat menghasilkan harga rata-rata per saham yang lebih menguntungkan seiring waktu. Selain itu, rencana tabungan saham juga memungkinkan investor kecil untuk mengakses saham-saham mahal, karena mereka dapat berpartisipasi dengan jumlah yang kecil. Investasi rutin juga mendukung strategi investasi yang disiplin dan membantu menghindari keputusan emosional, seperti membeli atau menjual secara impulsif. Di samping itu, investor juga mendapat manfaat dari potensi peningkatan nilai saham serta dari pembagian dividen, yang bisa direinvestasikan, meningkatkan efek bunga majemuk dan dengan demikian pertumbuhan dari modal yang diinvestasikan.